Tag:
LX6171
Latest Headlines
Latest Headlines
Lexicon memory drug flunks Phase II
Lexicon Pharmaceuticals has opted to halt development of its memory improvement therapy after the drug flunked a Phase II trial. LX6171 was studied in subjects with age-associated memory impairment
